翰思艾泰生物医药科技（武汉）股份有限公司（股票名称：翰思艾泰-B，股票代码：03378）于2026年6月30日披露翌日披露报表，宣布在香港联交所场内回购股份。
公告显示，2026年6月30日该公司回购H股普通股69,600股，占本次回购前已发行股份（不包括库藏股）总数134,592,830股的约0.052%。每股回购价在每股27.00港元至28.30港元之间，总成交金额1,950,184港元，折合约195.02万港元。回购完成后，公司已发行股份数为134,523,230股，库藏股为1,695,600股，合计136,218,830股。
根据公告，购回授权的决议于2026年6月24日获通过，公司可购回股份总数为13,469,683股。截至公告日，根据该授权已回购173,600股，占授权通过当日已发行股份（不包括库藏股）总数的约0.1289%。公司方面确认已遵守香港联合交易所有限公司证券上市规则及相关法律规定。公告由董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.